Experimental CAR t therapy targets lupus and related diseases – but trial ends early
NCT ID NCT06462144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the immune system. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital Of Xuzhou Medical University
Xuzhou, Jiangsu, 221004, China
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
Zhongshan Hospital Fudan University.
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a targeted antibody tame kidney inflammation without heavy steroids?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Eye tests could spot silent vision damage in lupus patients
- Could a simple blood test predict lupus in children with ITP?